Nimbus-T Global | Secure Identity Management
  • Home
  • Nimbus-Key
    • Secure Identity
    • Smart directory
    • Secure Messaging
    • Telehealth
    • Blockchain
  • Cyber Guide
  • About
Select Page
Can a cancer treatment work on COVID-19?

Can a cancer treatment work on COVID-19?

by Duke-NUS | Apr 27, 2020 | news, Covid-19 / Coronavirus, Oncology

Researchers are exploring engineering specific virus-targeting receptors onto a patient’s own immune cells as a way to fight infectious diseases, including COVID-19.

Grail validation data show highly accurate detection of cancers, tissues of origin

Grail validation data show highly accurate detection of cancers, tissues of origin

by Alaric DeArment | Oct 14, 2019 | Cybersecurity, news, Oncology

A test in development for early detection of cancers was able to pick up a dozen of the deadliest cancer types at stages I-IV with a high degree of accuracy while also determining where the tumor was located, according to validation data announced Monday.

Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership

Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership

by Alaric DeArment | Sep 5, 2019 | Biopharma, Healthcare Innovation

A large biotech company is pouring tens of millions of dollars into a German firm under a partnership to develop cell therapies in oncology.

Roche drug is third to win biomarker-driven cancer approval from FDA

Roche drug is third to win biomarker-driven cancer approval from FDA

by Alaric DeArment | Aug 23, 2019 | Biopharma

Another drug designed to treat cancer patients based on a genetic driver rather than where tumors occur in the body has received approval from the Food and Drug Administration.

Kite Pharma founder’s venture capital firm closes new $600M fund

Kite Pharma founder’s venture capital firm closes new $600M fund

by Alaric DeArment | Aug 6, 2019 | Biopharma, Oncology

Boston-based Vida Ventures said Thursday that it had closed its Vida Ventures II, or Vida II fund, raising $600 million.

Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B

Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B

by Kevin Truong | Aug 5, 2019 | Biopharma

Exact Sciences has agreed to purchase Genomic Health in a $2.8 billion cash-and-stock deal to create a powerhouse in the oncology diagnostics industry.

« Older Entries

Blog Stats

  • 32,713 hits

Recent Posts

  • 24 Alarming Cybercrime Statistics For 2021
  • More Countries Officially Blame Russia for SolarWinds Attack
  • Cloud Forensics Firm Cado Security Raises $10 Million in Series A Funding
  • As filing season and tax-law changes loom, the IRS stresses identity security
  • Microsoft Identity Division Embracing Blockchain for Decentralized IDs

Categories

  • AI
  • Banking
  • Big Data
  • Biopharma
  • Blockchain
  • Clinical Trials
  • Concierge Medicine
  • Covid-19 / Coronavirus
  • Cryptocurrency
  • Cybersecurity
  • Digital Health
  • EMR
  • Encryption
  • Fraud
  • Funding
  • Genomics
  • Hacked
  • Health Insurance
  • Healthcare Costs
  • Healthcare Innovation
  • Hospital News
  • Hospital Security
  • Identity Management
  • Investment Opportunity
  • news
  • Oncology
  • Patient Identity
  • Precision Medicine
  • Ransomware
  • Telehealth
  • Venture Capital

Nimbus-T Global inc

21 Orinda Way #C-280
Orinda, CA 94562

info@nimbus-t.com

Translation


 Edit Translation
Powered by Nimbus-T Global Inc. © 2021 All Rights Reserved